Hispanolistic/E+ via Getty Images As we move throughout the Q1 earnings season amid all-time highs for the S&P 500, post-earnings reactions are proving to be quite volatile, especially in the software industry. Investors are hypersensitive to the durability of software businesses amid the onset of the AI revolution. In many cases, earnings are providing a sharp relief rally in stocks that have bee...
Hispanolistic/E+ via Getty Images As we move throughout the Q1 earnings season amid all-time highs for the S&P 500, post-earnings reactions are proving to be quite volatile, especially in the software industry. Investors are hypersensitive to the durability of software businesses amid the onset of the AI revolution. In many cases, earnings are providing a sharp relief rally in stocks that have been declining for a while, as was the case with Commerce.com ( CMRC ). Investors cheered the company's acceleration in GMV and pricing updates that have apparently stabilized the top line, leading to a 20%+ post-earnings jump. The stock remains down ~30% over the past year, so the key question is: H as Commerce.com begun a rebound rally, or is this a dead cat bounce? Data by YCharts I last wrote a "Sell" article on Commerce.com in February, when the stock was trading at just shy of $3 per share. I certainly didn't predict the return of enthusiasm for this name post-Q2. That said, I still think many glaring issues remain here, which make me uncomfortable investing in this stock for the long haul. I reiterate my "Sell" opinion here. To be sure, there are many merits in Commerce.com's recent execution that we must applaud. At the same time, I don't view the company as "out of the woods" just yet, and its far inferior growth position is a core justification for why its stock trades at such low multiples. We note that despite the Q1 beat, Commerce.com didn't actually raise its full-year growth outlook of 5% y/y or its profitability expectations. The company's Q2 outlook, which calls for 1% y/y growth, implies yet another quarter of deceleration. We would hope that with Commerce.com posting such tepid growth rates that the company would be able to announce deeper headcount reductions or efficiency measures; this hasn't yet happened. Commerce.com outlook (Commerce.com Q1 earnings deck) Value remains Commerce.com's main selling point. At current share prices near $4, Commerce.com tra...
Taxi-hailing app operator Go Inc. is targeting a valuation of about ¥200 billion ($1.3 billion) for its initial public offering that may raise as much as ¥90 billion, according to people familiar with the matter. The Goldman Sachs Group Inc. -backed company may announce the IPO as soon as next week and aims to list in mid-June, said the people who asked not to be identified as the information was ...
Taxi-hailing app operator Go Inc. is targeting a valuation of about ¥200 billion ($1.3 billion) for its initial public offering that may raise as much as ¥90 billion, according to people familiar with the matter. The Goldman Sachs Group Inc. -backed company may announce the IPO as soon as next week and aims to list in mid-June, said the people who asked not to be identified as the information was not public. Discussions about the offer structure including size are still ongoing and details are subject to change, the people said. A spokesperson for Go didn’t respond to requests for comment. Japan’s most widely-used taxi-hailing provider has been working with banks including Bank of America Corp. , Goldman and Nomura Holdings Inc. on the IPO, Bloomberg News reported last month. Go’s taxi booking app has the highest user numbers in Japan, according to a survey in 2024 by ICT Research and Consulting Inc. Inside the country, it competes against Uber Technologies Inc., China-based Didi Global Inc. and local provider S.Ride Inc., which Sony Group Corp. has invested in. Goldman invested ¥10 billion in 2023 in a deal valuing Go at ¥135 billion, according to its president. Major shareholder DeNA Co. , which holds about a 26% stake, said in February that Go had submitted an application to list on the Tokyo Stock Exchange.
Concentra Group Holdings Parent ( CON ) declares $0.0625/share quarterly dividend , in line with previous. Forward yield 1.06% Payable June 9; for shareholders of record May 19; ex-div May 19. The company has now announced a dividend of $0.0625 for seven consecutive quarters. See CON Dividend Scorecard, Yield Chart, & Dividend Growth. More on Concentra Group Holdings Parent Concentra Group Holding...
Concentra Group Holdings Parent ( CON ) declares $0.0625/share quarterly dividend , in line with previous. Forward yield 1.06% Payable June 9; for shareholders of record May 19; ex-div May 19. The company has now announced a dividend of $0.0625 for seven consecutive quarters. See CON Dividend Scorecard, Yield Chart, & Dividend Growth. More on Concentra Group Holdings Parent Concentra Group Holdings Parent, Inc. (CON) Shareholder/Analyst Call Prepared Remarks Transcript Concentra Group Holdings Parent, Inc. (CON) Q4 2025 Earnings Call Transcript Concentra Group Holdings Parent, Inc. 2025 Q4 - Results - Earnings Call Presentation Concentra outlines $2.25B–$2.35B 2026 revenue target while expanding de novo and M&A strategy Seeking Alpha’s Quant Rating on Concentra Group Holdings Parent
Earnings Call Insights: Palvella Therapeutics (PVLA) Q1 2026 Management view CEO Wesley Kaupinen said the company is “positioned for our first potential FDA approval and U.S. commercial launch,” citing “decisively positive Phase III results for QTORIN rapamycin and microcystic lymphatic malformations,” a “strengthened balance sheet,” added commercial talent, and “an acceleration of our U.S. launch...
Earnings Call Insights: Palvella Therapeutics (PVLA) Q1 2026 Management view CEO Wesley Kaupinen said the company is “positioned for our first potential FDA approval and U.S. commercial launch,” citing “decisively positive Phase III results for QTORIN rapamycin and microcystic lymphatic malformations,” a “strengthened balance sheet,” added commercial talent, and “an acceleration of our U.S. launch readiness.” Kaupinen said the Phase III SELVA study “achieved its primary endpoint and all prespecified key secondary and secondary endpoints,” and he emphasized a profile he believes can support “first-line standard of care positioning” in microcystic lymphatic malformations. Kaupinen said the NDA “remains on track for the second half of 2026,” adding, “the FDA has granted Palvella an in-person pre-NDA meeting to be held later this quarter.” Kaupinen described an expanded launch build, including a “field sales force between 30 to 40 reps,” and said Palvella hired commercial leaders Jennifer McDonough and Kent Taylor, alongside Chief Commercial Officer Ashley Kline. Kaupinen framed commercial potential by stating, “We estimate peak U.S. sales potential of greater than $1 billion in microcystic lymphatic malformations for QTORIN rapamycin,” supported by “estimated diagnosed prevalence of greater than 30,000 patients” and “orphan pricing within our previously guided range of $100,000 to $200,000 per patient per year.” CFO Matthew Korenberg said, “Palvella ended Q1 with $261.9 million in cash and cash equivalents,” and tied runway confidence to the “oversubscribed $230 million equity offering,” adding the company expects cash to last “well into a potential commercial launch.” Outlook Management reiterated timing targets: Kaupinen said the NDA is “on track for the second half of 2026,” while Korenberg said the company is “on track for an NDA submission in the second half of 2026 with the potential FDA approval targeted for the first half of 2027.” Kaupinen said the pre-NDA mee...
Earnings Call Insights: Arcturus Therapeutics (ARCT) Q1 2026 Management View “The first quarter of 2026 was a period of solid execution for Arcturus as we continue to advance our rare disease pipeline and strengthen our leadership team,” said CEO Joseph Payne, highlighting ARCT-032 progress: “Our 12-week Phase II study began enrollment in Q1. We are already well beyond one month of dosing.” Payne ...
Earnings Call Insights: Arcturus Therapeutics (ARCT) Q1 2026 Management View “The first quarter of 2026 was a period of solid execution for Arcturus as we continue to advance our rare disease pipeline and strengthen our leadership team,” said CEO Joseph Payne, highlighting ARCT-032 progress: “Our 12-week Phase II study began enrollment in Q1. We are already well beyond one month of dosing.” Payne framed repeat dosing as a differentiator in inhaled mRNA: “Continuous dosing beyond a month has never been successfully tolerated in the history of inhaled mRNA therapeutics,” and attributed tolerability to platform and manufacturing: “Our inhaled LUNAR particle technology includes key delivery lipids that are chemically different from all other technologies competing in this space,” and “our messenger RNA manufacturing process to remove undesired impurities is unique, proprietary and trade secreted.” Chief Medical Officer Alan Cohen said ARCT-032’s 12-week Phase II is intended to broaden the data package beyond short-term dosing: “The study is designed to monitor safety, tolerability and assess evidence of early clinical benefit,” including “changes in percent predicted FEV1 and lung clearance index,” plus “2 validated quality of life outcome measures” and “changes in high-resolution CT imaging.” CFO Dennis Mulroy reported liquidity and the company’s cost focus: “Cash, cash equivalents and restricted cash totaled $213.4 million on March 31, 2026, and $232.8 million on December 31, 2025.” He also said Arcturus “maintained a cash runway extending beyond the second quarter of 2028.” Outlook Payne set the near-term cadence around CF execution and regulatory milestones: “We look forward to collecting this clinical data, including lung function measures during and throughout this open-label Phase II study,” and later added, “later this year, we should have sufficient enrollment and data to inform our next steps.” On ARCT-810, Payne said the company’s FDA interaction provided a c...
NBH Holdings ( NBHC ) declares $0.32/share quarterly dividend , in line with previous. Forward yield 2.99% Payable June 15; for shareholders of record May 29; ex-div May 29. The company has now announced a dividend of $0.32 for two consecutive quarters. See NBHC Dividend Scorecard, Yield Chart, & Dividend Growth. More on NBH Holdings National Bank Holdings Corporation (NBHC) Q1 2026 Earnings Call ...
NBH Holdings ( NBHC ) declares $0.32/share quarterly dividend , in line with previous. Forward yield 2.99% Payable June 15; for shareholders of record May 29; ex-div May 29. The company has now announced a dividend of $0.32 for two consecutive quarters. See NBHC Dividend Scorecard, Yield Chart, & Dividend Growth. More on NBH Holdings National Bank Holdings Corporation (NBHC) Q1 2026 Earnings Call Transcript NBHC targets 2026 Q4 EPS above $1 as Vista integration drives ~10% loan growth and ~4% NIM outlook Seeking Alpha’s Quant Rating on NBH Holdings Historical earnings data for NBH Holdings Dividend scorecard for NBH Holdings
Staunton Country Park, Havant: Against my black fleece, this arachnid is startlingly vivid. In the fresh green of the beech canopy, it disappears The forecast had promised warm spring sunshine – ideal weather for a forest bathing class. Instead, a squally shower arrived without warning, and we ended up hugging tree trunks more out of necessity than mindfulness. In full leaf, the mature beech grove...
Staunton Country Park, Havant: Against my black fleece, this arachnid is startlingly vivid. In the fresh green of the beech canopy, it disappears The forecast had promised warm spring sunshine – ideal weather for a forest bathing class. Instead, a squally shower arrived without warning, and we ended up hugging tree trunks more out of necessity than mindfulness. In full leaf, the mature beech grove canopy would have kept us dry, but this early in the season, the leaves had only just unfurled, letting the rain through to saturate my jumper. For a while, we listened in silence as the foliage changed its voice, a dry whisper deepening into a steady, percussive patter. Thankfully, the downpour passed as quickly as it had arrived. Light filtered through the leaves, and we drifted back along the path until the trees opened into a small clearing. The instructor suggested that we sit on a semi-circle of fallen trunks, urging us to feel the texture of the rough-stalked feather moss ( Brachythecium rutabulum ) cushioning our makeshift benches. Flasks were passed around, the nettle and chamomile tea offering a welcome warmth. Continue reading...